Q-omics provides the consensus-scored LRRC8A profile across patient tissues and cancer cell-line models. LRRC8A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LRRC8A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, LRRC8A protein abundance shows 20,355 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where LRRC8A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC8A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC8A survival associations across molecular data types. LRRC8A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC8A RNA expression–survival associations across cancer types. High LRRC8A expression shows unfavorable associations in ACC, BLCA and HNSC, but favorable associations in KIRC, SCLC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LRRC8A RNA expression.
This table summarizes LRRC8A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC8A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC8A shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, COAD, LIHC and LUSC. The HNSC box plot shows higher LRRC8A RNA expression in tumor versus normal tissue (log2 FC = +1.353, t-test p < 0.001).
This table shows molecular features associated with LRRC8A in patient tissues and cancer cell lines. In patient samples, LRRC8A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC8A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
